VANCOUVER, BRITISH COLUMBIA--(Marketwire - July 21, 2008) - Tekmira Pharmaceuticals Corporation ("Tekmira") (TSX: TKM) announced today that it has selected ApoB SNALP and PLK1 SNALP as its two lead product candidates and plans to advance both into clinical development in 2009.
